Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.28 USD | +1.20% | -0.16% | +49.20% |
Financials (USD)
Sales 2024 * | 551M | Sales 2025 * | 587M | Capitalization | 2.4B |
---|---|---|---|---|---|
Net income 2024 * | -174M | Net income 2025 * | -193M | EV / Sales 2024 * | 3.97 x |
Net cash position 2024 * | 212M | Net Debt 2025 * | 234M | EV / Sales 2025 * | 4.48 x |
P/E ratio 2024 * |
-14
x | P/E ratio 2025 * |
-12.7
x | Employees | 1,453 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.74% |
Latest transcript on NovoCure Limited
1 day | +1.20% | ||
1 week | -0.16% | ||
Current month | +81.99% | ||
1 month | +81.99% | ||
3 months | +37.08% | ||
6 months | +81.54% | ||
Current year | +49.20% |
Managers | Title | Age | Since |
---|---|---|---|
Asaf Danziger
CEO | Chief Executive Officer | 56 | 01-12-31 |
Ashley Cordova
DFI | Director of Finance/CFO | 45 | 14-05-31 |
Moshe Giladi
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Doyle
CHM | Chairman | 61 | 03-12-31 |
Kin Yip Leung
BRD | Director/Board Member | 62 | 11-08-04 |
David Hung
BRD | Director/Board Member | 66 | 18-05-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.81% | 0 M€ | 0.00% | - | |
0.71% | 0 M€ | 0.00% | - | |
0.19% | 17 M€ | +5.91% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-30 | 22.27 | +1.18% | 1,206,816 |
24-05-29 | 22.01 | -1.39% | 1,590,411 |
24-05-28 | 22.32 | -3.59% | 1,537,470 |
24-05-24 | 23.15 | +3.77% | 816,024 |
24-05-23 | 22.31 | -5.86% | 1,385,287 |
Delayed Quote Nasdaq, May 30, 2024 at 03:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+49.20% | 2.37B | |
+75.69% | 12.57B | |
-25.26% | 7.42B | |
+7.63% | 6.74B | |
+12.43% | 5.34B | |
-15.78% | 4.78B | |
+28.18% | 4.62B | |
-21.40% | 3.69B | |
-21.90% | 2.9B | |
+0.50% | 1.95B |
- Stock Market
- Equities
- NVCR Stock